Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria

Inclusion Criteria: * Age ≥18 and ≤75 years * Urinary protein excretion \> 500 mg/g and ≤ 3500 mg/g in a 24-hr urine collection eGFR ≥ 25 mL/min/1.73m2 * On a stable dose of an ACEi or ARB for at least 4 weeks prior to randomization * Willing to sign informed consent * Women of Child-Bearing Potential (WOCBP): * WOCBP must be using an acceptable method of contraception to avoid pregnancy throughout the study and for up to 4 weeks after the last dose of study drug in such a manner that the risk of pregnancy is minimized. * WOCBP must have a negative serum or urine pregnancy test result (minimum sensitivity 25 IU/L or equivalent units of HCG) within 0 to 72 hours before the first dose of study drug. * Women must not be breast-feeding. WOCBP comprises women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or who are not post-menopausal. Exclusion Criteria: * Diagnosis of type 1 or type 2 diabetes mellitus * Urinary protein excretion \> 3500 mg/day * Peripheral Vascular Disease * Autosomal dominant polycystic kidney disease or autosomal recessive polycystic kidney disease, lupus nephritis, or ANCA-associated vasculitis * Indication for immunosuppressants as per the treating physician's judgment. * Receiving cytotoxic therapy, immunosuppressive therapy, or other immunotherapy for primary or secondary renal disease within 6 months prior to enrolment. * Active malignancy…